Literature DB >> 24700046

Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture.

Barry James O'Neill1, Sven O'hEireamhoin, David I Morrissey, Peter Keogh.   

Abstract

Bisphosphonate use has been identified as a contributory factor in atypical subtrochanteric fracture of the femur. These fractures are commonly treated with an intramedullary device. We present a case of implant failure of an intrameduallary device caused by non-union of an atypical subtrochanteric fracture.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24700046      PMCID： PMC3987542          DOI： 10.1136/bcr-2013-203519

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  23 in total

Review 1.  Can bisphosphonates be given to patients with fractures?

Authors:  H Fleisch
Journal:  J Bone Miner Res       Date:  2001-03       Impact factor: 6.741

Review 2.  The anabolic and catabolic responses in bone repair.

Authors:  D G Little; M Ramachandran; A Schindeler
Journal:  J Bone Joint Surg Br       Date:  2007-04

3.  Alendronate for the treatment of osteoporosis in men.

Authors:  E Orwoll; M Ettinger; S Weiss; P Miller; D Kendler; J Graham; S Adami; K Weber; R Lorenc; P Pietschmann; K Vandormael; A Lombardi
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

4.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

5.  Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.

Authors:  T Mashiba; C H Turner; T Hirano; M R Forwood; C C Johnston; D B Burr
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

6.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

7.  The relation between bisphosphonate use and non-union of fractures of the humerus in older adults.

Authors:  D H Solomon; M C Hochberg; H Mogun; S Schneeweiss
Journal:  Osteoporos Int       Date:  2008-10-09       Impact factor: 4.507

8.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

9.  Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.

Authors:  Matthijs P Somford; Frits W Draijer; Bregje J W Thomassen; Pascale M Chavassieux; Georges Boivin; Socrates E Papapoulos
Journal:  J Bone Miner Res       Date:  2009-10       Impact factor: 6.741

10.  Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength.

Authors:  Per Bosemark; Hanna Isaksson; Michelle M McDonald; David G Little; Magnus Tägil
Journal:  Acta Orthop       Date:  2013-02       Impact factor: 3.717
View more
  2 in total

1.  Total Hip Arthroplasty for Implant Rupture after Surgery for Atypical Subtrochanteric Femoral Fracture.

Authors:  Yu Ozaki; Tomonori Baba; Hironori Ochi; Yasuhiro Homma; Taiji Watari; Mikio Matsumoto; Kazuo Kaneko
Journal:  Case Rep Orthop       Date:  2016-10-12

2.  Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study.

Authors:  H P Bögl; K Michaëlsson; G Zdolsek; J Höijer; J Schilcher
Journal:  Osteoporos Int       Date:  2020-01-13       Impact factor: 4.507
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.